Stonepine Capital Management’s IN8bio INAB Stock Holding History

Stonepine Capital Management’s Portfolio INAB Stock Details INAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$980K	Buy	695,287 +31,875	+5%	+$48K	0.55%	42
2026 Q1	$982K	Buy	663,412 +498,519	+302%	+$964K	0.39%	35
2025 Q4	$386K	Buy	164,893 +5,472	+3%	+$10.4K	0.28%	51
2025 Q3	$346K	Buy	159,421 +76,991	+93%	+$169K	0.28%	49
2025 Q2	$172K	Buy	+82,430	New	+$335K	0.17%	51

Other funds holding INAB

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BCM

BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Oppenheimer & Co New York $9.37B AUM 36.4% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

CAPTRUST Financial Advisors Raleigh, North Carolina $65.5B AUM 24.25% 1-Year Est. Return

Stonepine Capital Management's INAB Position: Q2 2026 in Review

Stonepine Capital Management increased its IN8bio (INAB) stake by 4.8% in Q2 2026, buying an estimated $48K and bringing the position to 695,287 shares worth $980K. The position accounts for 0.55% of the portfolio, ranked #42.

Stonepine Capital Management first reported a position in INAB in Q2 2025 and has held it in 5 quarters since. The position peaked at $982K in Q1 2026. 21 funds tracked by Wall St. Rank hold INAB as of Q2 2026.

Stonepine Capital Management held 695,287 shares of IN8bio worth $980K as of Q2 2026.
Stonepine Capital Management bought 31,875 IN8bio shares in Q2 2026, an estimated $48K.
IN8bio made up 0.55% of Stonepine Capital Management's portfolio in Q2 2026, its #42 holding.
Stonepine Capital Management first reported a position in IN8bio in Q2 2025 and has held it in 5 quarters since.
Stonepine Capital Management's IN8bio position peaked at $982K in Q1 2026.
21 funds tracked by Wall St. Rank held IN8bio as of Q2 2026.

Based on Stonepine Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.